Cara Therapeutics announced that difelikefalin—its treatment for moderate to severe pruritus in atopic dermatitis patients—was selected for a late-breaker presentation at the 2022 American Academy of Dermatology annual meeting.
Cara Therapeutics, an early commercial-stage biopharmaceutical company, announced biomarker data from the KARE phase 2 clinical trial (NCT04018027) evaluating oral difelikefalin (Korsuva; Cara Therapeutics) will be presented in a late-breaking oral presentation at the 2022 American Academy of Dermatology (AAD) annual meeting, March 25-29, 2022, Boston, Massachusetts. Difelikefalinis being investigatedfor the treatment of moderate to severe pruritus in atopic dermatitis (AD) patients.
The presentation titled, “Oral Difelikefalin Improves Itch and Inflammatory Biomarkers in Atopic Dermatitis Subjects With Moderate-to-Severe Pruritus” will be held on Saturday March 26, with Paola Facheris, MD, Icahn School of Medicine at Mount Sinai, New York, New York and Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Italy, presenting the data.
Cara Therapeutics is also having a virtual R&D event at 1:00 p.m. EST on March 11, 2022, which will focus on the initiation of Oral difelikefalinphase 3 programs for the treatment of pruritus in patients with non-dialysis dependent advanced chronic kidney disease and AD, respectively, the press release continued. The presenters for this include:
For more AAD annual meeting coverage, be sure to go to DermatologyTimes.com.
Cara Therapeutics announces oral Korsuva(Difelikefalin) data selected for late-breaking presentation at 2022 American Academy of Dermatology annual meeting. Cara therapeutics. Press release. Published March 8, 2022. Accessed March 10, 2022. https://ir.caratherapeutics.com/news-releases/news-release-details/cara-therapeutics-announces-oral-korsuvatm-difelikefalin-data